DVA
DaVita Inc
$
129.050
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
130.655
Open
129.500
VWAP
129.18
Vol
850.17K
Mkt Cap
9.24B
Low
128.870
Amount
109.83M
EV/EBITDA(TTM)
7.67
Total Shares
87.70M
EV
20.70B
EV/OCF(TTM)
11.11
P/S(TTM)
0.81
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
3.32B
+2.96%
2.401
+20.03%
3.42B
+3.87%
2.765
+23.44%
3.43B
+5.18%
3.194
+23.32%
Estimates Revision
The market is revising Upward the revenue expectations for DaVita Inc. (DVA) for FY2025, with the revenue forecasts being adjusted by 2.45% over the past three months. During the same period, the stock price has changed by -10.65%.
Revenue Estimates for FY2025
Revise Upward
+2.45%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-2.9%
In Past 3 Month
Stock Price
Go Down
-10.65%
In Past 3 Month
6 Analyst Rating
20.63% Upside
Wall Street analysts forecast DVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVA is 155.67 USD with a low forecast of 145.00 USD and a high forecast of 169.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
5 Hold
1 Sell
Hold
20.63% Upside
Current: 129.050
Low
145.00
Averages
155.67
High
169.00
20.63% Upside
Current: 129.050
Low
145.00
Averages
155.67
High
169.00
Truist
David MacDonald
Hold
downgrade
$164 -> $148
2025-08-08
New
Reason
Truist
David MacDonald
Price Target
$164 -> $148
2025-08-08
New
downgrade
Hold
Reason
Truist analyst David MacDonald lowered the firm's price target on DaVita to $148 from $164 and keeps a Hold rating on the shares. The firm is adjusting its estimates to reflect the company's Q2 results, raising its FY25 EPS view by 14c to $10.88 but cutting its price target to reflect a lower assumed multiple, the analyst tells investors in a research note.
Barclays
Equal Weight
downgrade
$169 -> $160
2025-08-07
New
Reason
Barclays
Price Target
$169 -> $160
2025-08-07
New
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on DaVita to $160 from $169 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says DaVita's treatment growth and revenue per treatment were revised down as cyberattack disruptions drove higher missed treatment rates and revenue cycle challenges.
TD Cowen
Hold
downgrade
$157 -> $154
2025-08-07
New
Reason
TD Cowen
Price Target
$157 -> $154
2025-08-07
New
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on DaVita to $154 from $157 and keeps a Hold rating on the shares. The firm notes the company beat consensus EBIT but reiterated FY25 guide given lower expected tx and RPT growth. Patient care cost performance and international expected to offset. The continued tepid volume growth is weighing on shares and will likely continue to be the main investor debate, but TD Cowen sees management navigating this and achieving FY25 guidance.
Deutsche Bank
Hold
downgrade
$165 -> $137
2025-08-06
New
Reason
Deutsche Bank
Price Target
$165 -> $137
2025-08-06
New
downgrade
Hold
Reason
Deutsche Bank lowered the firm's price target on DaVita to $137 from $165 and keeps a Hold rating on the shares.
TD Cowen
Gary Taylor
Hold
downgrade
$165 -> $157
2025-05-19
Reason
TD Cowen
Gary Taylor
Price Target
$165 -> $157
2025-05-19
downgrade
Hold
Reason
TD Cowen analyst Gary Taylor lowered the firm's price target on DaVita to $157 from $165 and keeps a Hold rating on the shares. The firm updated its model following Q1 results after they missed adjusted EBIT estimates due to higher flu and weather impacts.
Truist
Hold
downgrade
$170 -> $164
2025-05-19
Reason
Truist
Price Target
$170 -> $164
2025-05-19
downgrade
Hold
Reason
Truist lowered the firm's price target on DaVita to $164 from $170 and keeps a Hold rating on the shares. The firm has adjusted its estimates to reflect the company's Q1 results and notes that while it remains positive on its core dialysis business and the potential opportunity tied to integrated care longer term, it also views its near-term fundamentals as mixed, with improved capital efficiency to be somewhat offset by slower organic volume trends, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for DaVita Inc (DVA.N) is 11.31, compared to its 5-year average forward P/E of 13.01. For a more detailed relative valuation and DCF analysis to assess DaVita Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
13.01
Current PE
11.31
Overvalued PE
14.84
Undervalued PE
11.19
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
9.53
Current EV/EBITDA
8.30
Overvalued EV/EBITDA
10.30
Undervalued EV/EBITDA
8.75
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
0.87
Current PS
0.68
Overvalued PS
1.03
Undervalued PS
0.70
Financials
Annual
Quarterly
FY2025Q2
YoY :
+6.05%
3.38B
Total Revenue
FY2025Q2
YoY :
+8.50%
543.48M
Operating Profit
FY2025Q2
YoY :
-8.18%
275.22M
Net Income after Tax
FY2025Q2
YoY :
+3.20%
2.58
EPS - Diluted
FY2025Q2
YoY :
-70.01%
203.30M
Free Cash Flow
FY2025Q2
YoY :
+2.38%
27.91
Gross Profit Margin - %
FY2025Q2
YoY :
-4.02%
9.80
FCF Margin - %
FY2025Q2
YoY :
-13.50%
8.14
Net Margin - %
FY2025Q2
YoY :
+6.28%
11.00
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 729.61% over the last month.
Sold
0-3
Months
230.4M
USD
2
3-6
Months
27.8M
USD
3
6-9
Months
147.7M
USD
4
0-12
Months
9.9M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 6939.07% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
953.1K
Volume
1
6-9
Months
13.5K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
4.7K
Volume
Months
6-9
1
260.4K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
8.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 729.61% over the last month.
Sold
0-3
Months
230.4M
USD
2
3-6
Months
27.8M
USD
3
6-9
Months
147.7M
USD
4
0-12
Months
9.9M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DVA News & Events
Events Timeline
2025-08-05 (ET)
2025-08-05
16:14:06
DaVita reports Q2 adjusted EPS $2.95, consensus $2.75
2025-05-30 (ET)
2025-05-30
14:36:45
DaVita 'applauds' CMMI decision to extend Kidney Care Choices Model
2025-05-12 (ET)
2025-05-12
16:07:09
DaVita backs FY25 adjusted EPS view $10.20-$11.30, consensus $11.03
Sign Up For More Events
Sign Up For More Events
News
2.0
08-06NASDAQ.COMStocks Rally on Positive Corporate News and Fed Rate Cut Hopes
4.5
08-06NASDAQ.COMWednesday Sector Laggards: Paper & Forest Products, Diagnostics
8.0
08-06NASDAQ.COMNoteworthy Wednesday Option Activity: ROK, LULU, DVA
Sign Up For More News
People Also Watch
FMS
Fresenius Medical Care AG
24.110
USD
+0.17%
RNR
Renaissancere Holdings Ltd
240.430
USD
+0.02%
CRDO
Credo Technology Group Holding Ltd
118.570
USD
-1.53%
VTRS
Viatris Inc
9.860
USD
+1.65%
UDR
UDR Inc
37.500
USD
-1.55%
CAVA
CAVA Group Inc
82.300
USD
-3.23%
XPEV
Xpeng Inc
21.380
USD
+5.84%
TOL
Toll Brothers Inc
124.180
USD
-1.27%
PKX
Posco Holdings Inc
54.940
USD
+2.37%
FAQ
What is DaVita Inc (DVA) stock price today?
The current price of DVA is 129.05 USD — it has decreased -0.35 % in the last trading day.
What is DaVita Inc (DVA)'s business?
What is the price predicton of DVA Stock?
What is DaVita Inc (DVA)'s revenue for the last quarter?
What is DaVita Inc (DVA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for DaVita Inc (DVA)'s fundamentals?
How many employees does DaVita Inc (DVA). have?